JPH07138179A - Cell activator containing extract from belamcanda chinensis dc. and its application - Google Patents
Cell activator containing extract from belamcanda chinensis dc. and its applicationInfo
- Publication number
- JPH07138179A JPH07138179A JP5309858A JP30985893A JPH07138179A JP H07138179 A JPH07138179 A JP H07138179A JP 5309858 A JP5309858 A JP 5309858A JP 30985893 A JP30985893 A JP 30985893A JP H07138179 A JPH07138179 A JP H07138179A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- cell activator
- test
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 37
- 239000012190 activator Substances 0.000 title claims abstract description 8
- 241000596154 Belamcanda Species 0.000 title abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 230000003213 activating effect Effects 0.000 claims abstract description 6
- 241001113425 Iridaceae Species 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract 2
- 229920005862 polyol Polymers 0.000 claims abstract 2
- 150000003077 polyols Chemical class 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 235000014486 Hydrangea macrophylla Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 241001092080 Hydrangea Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 22
- 206010052428 Wound Diseases 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 230000003796 beauty Effects 0.000 abstract description 3
- 238000003287 bathing Methods 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 14
- 229940058015 1,3-butylene glycol Drugs 0.000 description 13
- 235000019437 butane-1,3-diol Nutrition 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 230000036284 oxygen consumption Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000013009 Pyruvate Kinase Human genes 0.000 description 7
- 108020005115 Pyruvate Kinase Proteins 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- -1 pack Substances 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 239000013040 bath agent Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 241000218691 Cupressaceae Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- CNOURESJATUGPN-UDEBZQQRSA-N tectoridin Chemical compound C1=C2OC=C(C=3C=CC(O)=CC=3)C(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNOURESJATUGPN-UDEBZQQRSA-N 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 240000005109 Cryptomeria japonica Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- RISXUTCDCPHJFQ-UHFFFAOYSA-N Irisflorentin Chemical compound COC1=C(OC)C(OC)=CC(C=2C(C3=C(OC)C=4OCOC=4C=C3OC=2)=O)=C1 RISXUTCDCPHJFQ-UHFFFAOYSA-N 0.000 description 2
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 241000915604 Scutellaria barbata Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FHFSSMDJUNVMNY-UHFFFAOYSA-N tectoridin Natural products COc1c(O)c2C(=O)C(=COc2cc1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 FHFSSMDJUNVMNY-UHFFFAOYSA-N 0.000 description 2
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- CCZHKEJGAJVDRC-UHFFFAOYSA-N Belamcanidin Natural products C1=C(OC)C(OC)=CC=C1C1=COC2=CC(OC)=C(OC)C(O)=C2C1=O CCZHKEJGAJVDRC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LNQCUTNLHUQZLR-VNPYQEQNSA-N Iridin Natural products O(C)c1c(O)c2C(=O)C(c3cc(OC)c(OC)c(O)c3)=COc2cc1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LNQCUTNLHUQZLR-VNPYQEQNSA-N 0.000 description 1
- PBVMPAHKYVXSHF-UHFFFAOYSA-N Irigenin Natural products COc1cc(OC)c(C2=COc3cc(O)cc(O)c3C2=O)c(OC)c1O PBVMPAHKYVXSHF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000013584 Tabebuia pallida Nutrition 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940056737 guinea pig skin extract Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- TUGWPJJTQNLKCL-UHFFFAOYSA-N irigenin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O)C=C3OC=2)=O)=C1 TUGWPJJTQNLKCL-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- PYJBVGYZXWPIKK-UHFFFAOYSA-M potassium;tetradecanoate Chemical compound [K+].CCCCCCCCCCCCCC([O-])=O PYJBVGYZXWPIKK-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 244000045561 useful plants Species 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
【0001】本発明は、植物由来の新規な細胞賦活剤と
その応用に関するものである。さらに詳しくは、アヤメ
科植物(Iridaceae)のヒオウギ(Belamcanda chinensi
s L.)、またはその根茎の乾燥物(生薬名:射干)から
の抽出物を含有する有用かつ安全性の高い細胞賦活剤と
その応用法を提供するものである。[0001] The present invention relates to a novel plant-derived cell activator and its application. More specifically, Iridaceae plants (Belamcanda chinensi)
s L.) or a dried product of the rhizome of the rhizome (crude drug name: irrigation) and a useful and highly safe cell activator and its application method.
【0002】[0002]
【産業上の利用分野】本発明によるヒオウギの抽出物
は、細胞に対して優れた賦活作用があり、しかも極めて
安全性が高い。よって例えば、皮膚外用剤,頭皮・頭髪
用剤,浴用剤といった各種の外用製剤類に配合して用い
ることによって、細胞の代謝を活性化し皮膚の老化を防
止したり、あるいは肌質の改善や創傷治癒といった美容
的効果が期待できる。具体的には、ローション,乳液,
クリーム,オイル,パック,シャンプー,リンス,ヘア
ートニック,ヘアーリキッド,ボディーソープ,あるい
は浴用剤(液状,粉末状,顆粒状,固形状など性状は、
何れであってもよい)などへの応用が上げられる。また
標記のような外用製剤の他にも、例えば栄養補強(栄養
補助)などを目的とするような健康維持のための食品や
飲料といったものにも配合して用いることもできる。The field of Hyogi according to the present invention has an excellent activating effect on cells and is extremely safe. Therefore, for example, when used in combination with various external preparations such as a skin external preparation, a scalp / hair preparation, and a bath preparation, cell metabolism is activated and skin aging is prevented, or skin quality is improved and wounds are improved. A cosmetic effect such as healing can be expected. Specifically, lotion, emulsion,
Cream, oil, pack, shampoo, rinse, hairnic, hair liquid, body soap, or bath agent (liquid, powder, granule, solid, etc.
It can be applied to any). In addition to the external preparations such as those mentioned above, they can also be used by blending them with foods and drinks for maintaining health for the purpose of nutritional supplementation.
【0003】[0003]
【従来の技術】植物の中には、いろいろな疾患に対する
治療または抑制的効果があったり、あるいは種々の有用
な生理活性が認められたりするものがあり、そうした有
用な植物は古くから健康維持のために広く利用されてき
た。本発明で用いるアヤメ科植物のヒオウギ(根茎の乾
燥物は、生薬名:射干と呼ばれる)は、消炎,鎮咳・去
痰作用,あるいは抗微生物作用といった効果があるとさ
れ、特に、咽痛,喉痺,気管支喘息などの治療に民間薬
的に利用されてきた植物である。ヒオウギ中に含まれる
成分としては、イリゲニン(Irigenin),テクトリゲニ
ン(Tectorigenin)、あるいはそれらの配糖体であるイ
リジン(Iridin),テクトリジン(Tectoridin)、その
他ベラムカンジン(Belamcandin),イリスフロレンチ
ン(Irisflorentin)などのイソフラボン化合物が確認
されている。また薬理作用については、例えば[中薬大
事典,小学館(1985.12.10)]などに記載されており、こ
れによればヒオウギ中のテクトリゲニンとテクトリジン
にヒアルロニダーゼ(I型アレルギーに関与している酵
素)阻害作用や、ヒオウギの煎剤や浸剤に病原性皮膚糸
状菌に対する抑制作用、またアルコール抽出物には血圧
降下作用などが認められている。ヒオウギの応用に関し
ては、例えば、特開昭63-30417号のヒオウギ中の5種の
イソフラボン化合物のPCA反応抑制作用(抗即時型ア
レルギー作用)による抗アレルギー剤としての利用や、
特公昭58-11922号に示される含水アルコール抽出物のチ
ロジナーゼ活性阻害作用による皮膚美白化粧料への応用
といったことが提唱されている。2. Description of the Related Art Some plants have a therapeutic or inhibitory effect on various diseases, or have various useful physiological activities, and such useful plants have long been used for health maintenance. Has been widely used for. The iris of the family Iridaceae used in the present invention (the dried product of rhizome is called crude drug name: suiho) is said to have effects such as anti-inflammatory, antitussive / expectorant action, or antimicrobial action, especially sore throat and sore throat. , A plant that has been used as a folk medicine for the treatment of bronchial asthma. Ingredients contained in Hyougi include irigenin, tectorigenin, or their glycosides iridin, tectoridin, belamcandin and irisflorentin. Isoflavone compounds have been confirmed. Further, the pharmacological action is described in, for example, [Encyclopedia of Chinese Medicine, Shogakukan (1985.12.10)] and the like, and according to this, hyaluronidase (enzyme involved in type I allergy) to tectorigenin and tectoridin in Japanese cedar. It has been observed that the inhibitory action, the decoction and the infusion of Hyougi against the pathogenic dermatophytes, and the alcohol extract has a hypotensive action. Regarding the application of Hyogi, for example, use as an anti-allergic agent by the PCA reaction inhibitory action (anti-immediate allergic action) of the five isoflavone compounds in Hyogi of JP-A-63-30417,
It has been proposed that the hydroalcoholic extract disclosed in Japanese Patent Publication No. 58-11922 is applied to skin whitening cosmetics by inhibiting the tyrosinase activity.
【0004】[0004]
【発明が解決しようとする課題】これまで、古くから伝
わる植物の有用性をもとに、その薬理作用や生理活性な
どについての生物学的な作用機序の解明や、またそれら
にもとづく応用法などが研究されてはきたものの、一般
的な日常生活に反映された形として積極的に有効利用が
はかられているものは未だ少ない。本発明者らは、細胞
の賦活というテーマをもとに美容と健康に役立つ植物成
分の検索と、その汎用的な利用法を検討してきた。その
過程において、アヤメ科植物のヒオウギの抽出物が、細
胞の賦活化に不可欠なATP(アデノシン三リン酸)の
産生に直接関与している解糖系の酵素:ピルビン酸キナ
ーゼに対し、優れた活性作用を示すことを見いだし、本
発明を完成した。DISCLOSURE OF INVENTION Problems to be Solved by the Invention Based on the usefulness of plants that have been transmitted for a long time, the elucidation of biological mechanism of action such as pharmacological action and physiological activity, and the application method based on them. Although such research has been conducted, there are still few that are actively used effectively as a form reflected in general daily life. The present inventors have searched for plant components useful for beauty and health based on the theme of cell activation, and have studied the general usage of the same. In the process, an extract of Hydrangea vulgaris superior to the glycolytic enzyme pyruvate kinase, which is directly involved in the production of ATP (adenosine triphosphate) essential for cell activation. The present invention was completed by discovering that it exhibits an active action.
【0005】[0005]
【課題を解決するための手段】細胞は、生物においてそ
れぞれの器官または組織の主要な部分を構成し、それら
の特殊な機能を主として担っている最少単位であり、そ
の機能を果たすために必要な物質をとり入れそれをもと
にした合成、分解、エネルギー保存、生成物の排出など
の機能とある程度の防御機構、そしてそれらの統合機能
をすべて備えている。これら細胞において、その分裂や
新生、あるいは機能の一部が低下した場合、生体は恒常
性を失い様々な症状や疾患などを招いたりすることか
ら、細胞の老化についての研究は生物学的あるいは医学
的な観点から、数多くの研究者らによって進められてき
た。[Means for Solving the Problems] A cell is a minimum unit that constitutes a major part of each organ or tissue in an organism and mainly has those special functions, and is necessary for fulfilling that function. It has all the functions of taking in substances, synthesizing, decomposing, storing energy, discharging products based on them, and some defense mechanism, and their integrated functions. In these cells, if the division, new generation, or part of the function is reduced, the living body loses homeostasis and causes various symptoms and diseases, so research on cell aging is biological or medical. It has been promoted by a number of researchers from an academic point of view.
【0006】特に、皮膚組織についてみれば、表皮,真
皮,皮下組織を構成する組織細胞は血液、リンパなどか
らの栄養素や調節因子などの制御を受けながら、相互に
関連して皮膚の構造や機能を保ち、生体の恒常性を維持
している。すなわち、表皮は外界からの刺激や異物の侵
入を防御したり、皮膚内部からの体液,電解質などの喪
失の防御(バリヤー機能)といったことに、また、真皮
は皮膚の支持組織としてそれぞれ重要な役割を果たして
いるのである。ところがこれら組織を形成する細胞の代
謝が何等かの要因によって衰え、増殖能や種々の機能の
低下を招くと、皮膚は潤いやつや、柔軟性、はりなどを
失い、シミやシワが増えたり、傷つき易くなったりす
る。また肉芽形成や創傷治癒速度が低下して、時には二
次的な疾患まで招いたりすることもある。In particular, regarding the skin tissue, the tissue cells constituting the epidermis, dermis and subcutaneous tissue are controlled by nutrients and regulatory factors from blood, lymph, etc. To maintain the homeostasis of the living body. In other words, the epidermis plays an important role in preventing external irritation and invasion of foreign substances, and in protecting the loss of body fluids and electrolytes from the inside of the skin (barrier function), and the dermis plays an important role as a supporting tissue of the skin. Is fulfilling. However, if the metabolism of the cells that form these tissues declines due to some factor, leading to a decrease in proliferative ability and various functions, the skin loses moisture, flexibility, and elasticity, and spots and wrinkles increase, It may be easily damaged. In addition, the rate of granulation and the rate of wound healing are reduced, sometimes leading to secondary diseases.
【0007】細胞が分裂,増殖,分化あるいは恒常性維
持などの働きをするためには、少なくともエネルギー源
であるATPの供給が必要不可欠である。そして皮膚細
胞における主要なATPの供給は、解糖系によるものと
して考えられている。その解糖系において、グルコース
からピルビン酸、乳酸に至るまでの反応には実に11種類
の酵素が関与していることが知られているが、ATP生
産に直接関与し、しかも不可逆的な反応(解糖系の律速
段階)であるホスホエノールピルビン酸からピルビン酸
への反応に関与している酵素は、ピルビン酸キナーゼ
(PK)である。したがって、この酵素の活性化は皮膚
細胞の賦活化に大きく関与しているものとの考えに基づ
き、モルモットの皮膚を用いた試験系で各種植物抽出物
のPK活性作用について評価を行った。その結果、ヒオ
ウギの抽出物に優れたPK活性作用が認められ、この事
実に基づいて、モルモット肝臓ホモジネイトの酸素消費
能力試験、および兎を用いた創傷治癒効果についても検
討した結果、何れにおいても有効性が認められ本発明を
完成するに至った。以下にその実施例を示し、本発明を
より詳しく説明する。In order for cells to perform functions such as division, proliferation, differentiation or homeostasis, at least supply of ATP which is an energy source is indispensable. The major supply of ATP in skin cells is considered to be due to glycolysis. In the glycolytic system, it is known that 11 kinds of enzymes are actually involved in the reaction from glucose to pyruvic acid and lactic acid, but it is directly involved in ATP production and is irreversible ( The enzyme involved in the reaction of phosphoenolpyruvate to pyruvate, which is the rate-determining step of glycolysis, is pyruvate kinase (PK). Therefore, based on the idea that the activation of this enzyme is greatly involved in the activation of skin cells, the PK activation action of various plant extracts was evaluated in a test system using guinea pig skin. As a result, an excellent PK activating action was observed in the extract of Hyougi, and based on this fact, the oxygen consumption test of guinea pig liver homogenate and the wound healing effect using rabbits were also examined. Therefore, the present invention was completed. Examples will be shown below to describe the present invention in more detail.
【0008】[0008]
【実施例】ピルビン酸キナーゼ(PK)活性作用[試料
の調整] ヒオウギの20%Ethanolによる抽出液 ヒオウギの20%1,3-Butylene glycolによる抽出液 ヒオウギのEthanol,1,3-Butylene glycol,水(1:1:3)
混液による抽出液 (尚、各抽出液の蒸発残分としては、0.5〜1.5%程度で
ある) [使用した動物] ハートレー系雌性モルモット,体重300g前後,各5匹 [試験方法] 1)試料の投与 モルモットの両腹側部をバリカンにて剪毛し、試験区及
び対照区とした。試験区にはヒオウギ抽出液を1mL含ま
せたリント布をテープで接着し、ポリエチレンフィルム
にて4時間固定した。対照区は、それぞれの溶媒にて同
様に処置した。この操作を1日1回、2週間連続して行
った。尚、剪毛は2日に1度行った。 2)皮膚抽出液の調整 各ヒオウギ抽出液の最終投与48時間後、モルモットを脱
血屠殺し、試験区および対照区皮膚を分離した。得られ
た皮膚をバリカンにて剪毛し、皮下組織を完全に除去し
た後、正確に2g分離しハサミで細切後、氷冷下20mLの
生理食塩水を加え超音波処理を行った。この懸濁液を5,
000G,20分間遠心分離し、その上清を皮膚抽出液とし
た。 3)酵素活性の測定 予め下記の基質混液を調整しておき、その4mLを採取し
これにモルモット皮膚抽出液100μLを加え、37℃,20分
間インキュベートする。 基質混液 Tris-HCl(pH=7.5) 100mL Phospho(enol)pyruvate 3Na 0.2g MgCl2 0.02g KCl 0.02g ADP 2Na 0.02g 判定は、生成されたピルビン酸を2,4-ジニトロフェニル
ヒドラジンと反応させ吸光度510nmを測定し、次式によ
り求めた。尚、酵素活性は、ビウレット法により求めた
タンパク質量に換算し、対照区を100%とした時の試験
区の活性をT表により区間推定した。[Examples] Pyruvate kinase (PK) activation action [Preparation of sample] Extract of 20% Ethanol of Hyogi Extract of 20% 1,3-Butylene glycol of Hyogi Extract of Ethanol, 1,3-Butylene glycol of water, water (1: 1: 3)
Extract by mixed solution (The evaporation residue of each extract is about 0.5 to 1.5%) [Animal used] Hartley female guinea pig, body weight around 300 g, 5 animals each [Test method] 1) Sample Administration Both sides of the guinea pig were shaved with hair clippers to prepare test and control groups. A lint cloth impregnated with 1 mL of an extract of Hyougi was adhered to the test section with a tape and fixed with a polyethylene film for 4 hours. The control section was similarly treated with each solvent. This operation was performed once a day for two consecutive weeks. The shearing was performed once every two days. 2) Preparation of skin extract 48 hours after the final administration of each extract of Hyougi, guinea pigs were sacrificed by bleeding and the skins of the test and control groups were separated. The obtained skin was shaved with a hair clipper to completely remove the subcutaneous tissue, accurately separated into 2 g, cut into small pieces with scissors, and sonicated by adding 20 mL of physiological saline under ice cooling. Add this suspension to 5,
After centrifugation at 000 G for 20 minutes, the supernatant was used as a skin extract. 3) Measurement of enzyme activity The following substrate mixture was prepared in advance, 4 mL of it was sampled, 100 μL of guinea pig skin extract was added to it, and the mixture was incubated at 37 ° C for 20 minutes. Substrate mixture Tris-HCl (pH = 7.5) 100mL Phospho (enol) pyruvate 3Na 0.2g MgCl 2 0.02g KCl 0.02g ADP 2Na 0.02g For determination, the generated pyruvic acid was reacted with 2,4-dinitrophenylhydrazine to determine the absorbance. 510 nm was measured and it calculated | required by the following formula. The enzyme activity was converted into the amount of protein determined by the Biuret method, and the activity of the test plot when the control plot was set to 100% was estimated from the T table.
【数1】 [試験結果]試験に用いた各ヒオウギの抽出液は、対照
区に比べ113.8〜117.3%(95%信頼区間)の酵素活性作
用で明かな優位差が認められた。[Equation 1] [Test Results] The extract of each Hyogi used in the test showed a significant difference in the enzyme activity of 113.8 to 117.3% (95% confidence interval) compared to the control group.
【0009】[0009]
【実施例】酸素消費能力試験 [試料の調整]ヒオウギの20%Ethanol抽出液を減圧下
で濃縮乾固し、精製水で0.0001%,および0.00001%溶
液を調整した。 [浮遊液 Krebs-Ringer Bicarbonate(KBR) の調整] 0.90%NaCl 100 mL 1.15%KCl 4 mL 1.22%CaCl2 3 mL 2.11%KH2PO4 1 mL 3.82%MgSO4・7H2O 1 mL 1.30%NaHCO3 21 mL 合計 130 mL 8.5%リン酸でpH=7.4に調整した。 [肝臓ホモジネートの調整]ハートレー系モルモット
(雌性)の肝臓を取り出し、生理食塩水でよく洗浄した
後、同量のKRBを加え氷水中でホモジナイズし、50%肝
臓ホモジネートを調整した。 [測定機器] TAIYO O2 UPTESTER (大洋科学工業株式会社製) [酸素消費量の測定]反応容器中に試料1.0mL,KRB2.0m
L,肝臓ホモジネート0.5mLを入れる。コントロールには
試料の代わりに精製水を等量加える。また肝臓ホモジネ
ートを添加しないブランクを設定する。容器のフタに、
CO2吸収剤(2N-NaOH)を湿らせたろ紙を貼り、密閉す
る。容器を37℃の恒温槽に入れ15分間インキュベートし
た後、測定を開始し、5分毎に毛細管を移動した水の量
を目盛板より読み取る。ブランクから大気圧等の影響に
より毛細管中を移動した空気量を求め、真の酸素消費量
を求める。 [試験結果]酸素消費量の経時変化を図1に示す。ヒオ
ウギの20%Ethanol抽出物は、モルモット肝細胞を用い
た酸素消費量テストにおいて、酸素の消費量を増大させ
る効果が得られた。本発明による他の溶媒の抽出物につ
いても同様に検討したが、これとほぼ同等な効果が得ら
れた。[Examples] Oxygen consumption capacity test [Preparation of sample] A 20% Ethanol extract solution of Japanese cedar was concentrated and dried under reduced pressure, and 0.0001% and 0.00001% solutions were prepared with purified water. [Suspension Krebs-Ringer Bicarbonate (KBR) Adjustment] 0.90% NaCl 100 mL 1.15% KCl 4 mL 1.22% CaCl 2 3 mL 2.11% KH 2 PO 4 1 mL 3.82% MgSO 4 · 7H 2 O 1 mL 1.30% NaHCO 3 21 mL Total 130 mL The pH was adjusted to 7.4 with 8.5% phosphoric acid. [Preparation of Liver Homogenate] The liver of a Hartley guinea pig (female) was taken out and washed thoroughly with physiological saline, and then the same amount of KRB was added and homogenized in ice water to prepare a 50% liver homogenate. [Measurement equipment] TAIYO O 2 UPTESTER (manufactured by Taiyo Kagaku Kogyo Co., Ltd.) [Measurement of oxygen consumption] 1.0 mL sample, KRB 2.0 m in reaction container
L, add 0.5 mL of liver homogenate. Instead of the sample, add equal amount of purified water to the control. Also, set a blank without addition of liver homogenate. On the lid of the container,
Attach filter paper moistened with CO 2 absorbent (2N-NaOH) and seal. The container is placed in a 37 ° C. thermostat and incubated for 15 minutes, then measurement is started, and the amount of water that has moved through the capillary tube is read from the scale plate every 5 minutes. The amount of air that has moved in the capillary from the blank under the influence of atmospheric pressure is calculated, and the true oxygen consumption is calculated. [Test Results] FIG. 1 shows the changes over time in oxygen consumption. A 20% Ethanol extract of Hyougi showed an effect of increasing oxygen consumption in an oxygen consumption test using guinea pig hepatocytes. The same examination was conducted on the extracts of other solvents according to the present invention, and the effect substantially equivalent to this was obtained.
【図1】[Figure 1]
【0010】[0010]
【実施例】創傷治癒効果 [被験薬物の調整] ヒオウギの20%Ethanolによる抽出液 ヒオウギのEthanolによる抽出液 ヒオウギの20%1,3-Butylene glycolによる抽出液 ヒオウギの1,3-Butylene glycolによる抽出液 ヒオウギの20%Propylene glycolによる抽出液 ヒオウギのEthanol,1,3-Butylene glycol,水(1:1:3)
混液による抽出液 (尚、各抽出液の蒸発残分としては、0.5〜1.5%程度で
ある) 上記の各ヒオウギ抽出液(2mL)を親水軟膏(10g)に混合
し、調整した。また対照としてそれぞれの溶媒のみを加
えたものを調整した。 [使用した動物] 白色日本家ウサギ,雌性,体重3,500g前後,3匹 [試験方法]ウサギの耳介内側を脱毛クリームにて除毛
し、24時間後、麻酔下で直径5mmのトレパン,ピンセッ
ト,メスにて深さ0.2mmの人工円形潰瘍を2箇所づつ、
約1cmの間隔で作成した。潰瘍部からの止血を確認した
後、左の耳介内面に試料の軟膏、右の耳介内面には対照
の軟膏を塗布した。翌日より、定時に潰瘍部を透明フィ
ルムに写しとり画像解析装置にて面積を測定した。尚、
軟膏の塗布は創傷の測定後に、1日1回行った。 [試験結果]試験開始後、10日目の面積は、各対照区1
4.4〜15.9mm2であるのに対し、試験区の方は、4.8〜5.7
mm2ですべての抽出液に効果が認められた。[Examples] Wound healing effect [Preparation of test drug] Extract of 20% Ethanol of sycamore extract of Ethanol of cypress Hyogi Extract of 20% of cypress extract of 1,3-Butylene glycol Extract of cypress of 1,3Butylene glycol Liquid Extract of 20% Propylene glycol from Scutellaria barbata Ethanol, 1,3-Butylene glycol, water (1: 1: 3)
Extract by mixed solution (The evaporation residue of each extract is about 0.5 to 1.5%) Each of the above-mentioned Hyougi extracts (2 mL) was mixed with a hydrophilic ointment (10 g) to adjust. Further, as a control, one prepared by adding only each solvent was prepared. [Animal used] White Japanese rabbit, female, body weight around 3,500 g, 3 animals [Test method] The inside of the auricle of the rabbit was shaved with a depilatory cream, and 24 hours later, under anesthesia, a trepan with a diameter of 5 mm and tweezers. , 2 artificial circular ulcers with a depth of 0.2 mm using a scalpel,
Created at intervals of about 1 cm. After confirming hemostasis from the ulcer site, a sample ointment was applied to the inner surface of the left auricle, and a control ointment was applied to the inner surface of the right auricle. From the next day, the ulcer part was regularly copied on a transparent film and the area was measured by an image analyzer. still,
The ointment was applied once a day after measuring the wound. [Test Results] The area on the 10th day after the start of the test is 1 for each control group.
4.4 ~ 15.9 mm 2 , whereas in the test area 4.8 ~ 5.7
The effect was observed for all extracts at mm 2 .
【0011】[0011]
【実施例】安全性試験 1)皮膚一次刺激性試験 ヒオウギのEthanol,1,3-Butylene glycol,水(1:1:3)
の抽出液(蒸発残分としては、1.4%程度)を、背部を
除毛した兎(1群3匹,体重3,800g前後)の皮膚に貼
付した。判定は、貼付後24,48,72時間に一次刺激性の
評点法により紅斑および浮腫を指標として行った。その
結果、すべての動物において、何等、紅斑および浮腫を
認めず陰性と判定された。 2)皮膚累積刺激性試験 ヒオウギのEthanol,1,3-Butylene glycol,水(1:1:3)
の抽出液(蒸発残分としては、1.4%程度)を、側腹部
を除毛(2×4cm2)したハートレー系モルモット(雌
性,1群5匹,体重320g前後)の皮膚に1日1回,週
5回,0.5mL/動物当りを塗布した。塗布は4週に渡っ
て、また除毛は各週の最終塗布日に行った。判定は、各
週の最終日の翌日に一次刺激性の評点法により紅斑およ
び浮腫を指標として行った。その結果、すべての動物に
おいて、塗布後1〜4週目に渡って何等、紅斑および浮
腫を認めず陰性と判定された。 3)急性毒性試験 ヒオウギのEthanol抽出液を減圧下にて溶媒を完全に留
去し、試験前、4時間絶食させたddy系マウス(1群5
匹,体重30g)に2,000mg/kg量経口投与し、毒性症状
の発現、程度などを経時的に観察した。その結果、すべ
てのマウスにおいて14日間何等異常を認めず、また解剖
の結果も異常がなかった。LD50は2,000mg/kg以上と判
定された。[Examples] Safety test 1) Primary skin irritation test Ethanol, 1,3-Butylene glycol, water (1: 1: 3)
The extract (about 1.4% as an evaporation residue) was applied to the skin of a rabbit whose back was hair-removed (3 animals per group, body weight around 3,800 g). The evaluation was performed 24, 48, and 72 hours after application by using the erythema and edema as indexes by the primary irritation scoring method. As a result, all animals were judged as negative without any erythema or edema. 2) Skin cumulative irritation test Ethanol, 1,3-Butylene glycol, water (1: 1: 3)
Once a day on the skin of the Hartley guinea pig (female, 5 animals per group, weight 320 g) with the hair removed from the flank (2 x 4 cm 2 ). , 0.5 mL / animal was applied 5 times a week. The application was carried out for 4 weeks, and the hair removal was performed on the last application day of each week. Judgment was performed on the day after the last day of each week, using erythema and edema as an index by the primary irritation scoring method. As a result, in all animals, erythema and edema were not observed for 1 to 4 weeks after application, and it was determined to be negative. 3) Acute toxicity test The solvent was completely distilled off under reduced pressure from Ethanol extract of Scutellaria barbata and fasted for 4 hours before the test.
Oral administration of 2,000 mg / kg to a mouse, body weight 30 g) was performed, and the onset and degree of toxic symptoms were observed over time. As a result, no abnormality was observed in all mice for 14 days, and there was no abnormality in the autopsy result. The LD 50 was determined to be 2,000 mg / kg or higher.
【0012】[0012]
【実施例】各種外用製剤の製造 本発明によるヒオウギ由来の細胞賦活剤を使用し、いく
らかの外用製剤を製造した。以下にその処方例を示す
が、本発明による細胞賦活剤の用途は、これらに限定さ
れるわけではない。 1)ローションの製造例 次の処方によりローションを製造した。 重量% 1.ソルビット 2 2.1,3−ブチレングリコール 2 3.ポリエチレングリコール1000 1 4.ポリオキシエチレンオレイルエーテル(25E.O.) 2 5.エタノール 10 6.ヒオウギ抽出液(20%Ethanol ex.) 10 7.pH調整剤 適量 8.防腐剤 適量 9.精製水 100とする残余 2)乳液の製造例 次の処方により乳液を製造した。 重量% 1.スクワラン 3 2.ワセリン 1 3.ステアリルアルコール 0.3 4.ソルビタンモノステアレート 1.5 5.ポリオキシエチレン(20)ソルビタンモノオレート 3 6.1,3−ブチレングリコール 5 7.ヒオウギ抽出液(20%1,3-Butylene glycol ex.) 5 8.防腐剤 適量 9.精製水 100とする残余 3)クリームの製造例 次の処方によりクリームを製造した。 重量% 1.スクワラン 20 2.ミツロウ 5 3.精製ホホバ油 5 4.グリセリンモノステアレート 2 5.ソルビタンモノステアレート 2 6.ポリオキシエチレン(20)ソルビタンモノステアレート 2 7.グリセリン 5 8.ヒオウギ抽出液(1,3-Butylene glycol ex.) 5 9.防腐剤 適量 10.精製水 100とする残余 4)シャンプーの製造例 次の処方によりシャンプーを製造した。 重量% 1.ラウリル硫酸トリエタノールアミン 5 2.ポリオキシエチレンラウリルエーテル硫酸Na 12 3.1,3−ブチレングリコール 4 4.ラウリン酸ジエタノールアミド 2 5.エデト酸二ナトリウム 0.1 6.ヒオウギ抽出液(20%1,3-Butylene glycol ex.) 10 7.防腐剤 適量 8.精製水 100とする残余 5)ヘアーリキッドの製造例 次の処方によりヘアーリキッドを製造した。 重量% 1.エタノール 29 2.ポリオキシプロピレンブチルエーテルリン酸 10 3.ポリオキシプロピレンモノブチルエーテル 5 4.トリエタノールアミン 1 5.ヒオウギ抽出液(Ethanol,1,3-BG,水(1:1:3)ex.) 5 6.防腐剤 適量 7.精製水 100とする残余 6)ボディーソープの製造例 次の処方によりボディーソープを製造した。 重量% 1.ラウリン酸カリウム 15 2.ミリスチン酸カリウム 5 3.プロピレングリコール 5 4.ヒオウギ抽出液(20%Propylene Glycol ex.) 15 5.pH調整剤 適量 6.防腐剤 適量 7.精製水 100とする残余 7)浴用剤(Aタイプ)の製造例 次の処方により浴用剤を製造した。 重量% 1.炭酸水素ナトリウム 58 2.無水硫酸ナトリウム 30 3.ホウ砂 2 4.ヒオウギ抽出液(40%Ethanol ex.)の乾燥粉末 10 8)浴用剤(Bタイプ)の製造例 次の処方により浴用剤を製造した。 重量% 1.精製ホホバ油 5 2.ポルオキシエチレンソルビタンモノラウレート 20 3.グリセリンモノステアレート 5 4.流動パラフィン 2 5.ラウリン酸ジエタノールアミド 3 6.ヒオウギ抽出液(50%Propylene glycol ex.) 25 7.精製水 100とする残余Examples Production of various external preparations Some external preparations were produced using the cell stimulant derived from Hyogi according to the present invention. The formulation examples are shown below, but the use of the cell activating agent according to the present invention is not limited to these. 1) Production Example of Lotion A lotion was produced according to the following formulation. Weight% 1. Sorbit 2 2.1,3-butylene glycol 2 3. Polyethylene glycol 1000 1 4. Polyoxyethylene oleyl ether (25E.O.) 2 5. Ethanol 10 6. Hyougi extract (20% Ethanol ex.) 10 7. pH adjuster Appropriate amount 8. Preservative proper amount 9. Residue of purified water 100 2) Production example of emulsion An emulsion was produced according to the following formulation. Weight% 1. Squalane 3 2. Vaseline 1 3. Stearyl alcohol 0.3 4. Sorbitan monostearate 1.5 5. Polyoxyethylene (20) sorbitan monooleate 3 6.1,3-butylene glycol 5 7. Hyougi extract (20% 1,3-Butylene glycol ex.) 58. Preservative proper amount 9. Residue with purified water as 100 3) Cream production example A cream was produced according to the following formulation. Weight% 1. Squalane 20 2. Beeswax 5 3. Refined jojoba oil 5 4. Glycerin monostearate 2 5. Sorbitan monostearate 2 6. Polyoxyethylene (20) sorbitan monostearate 2 7. Glycerin 5 8. Hyougi extract (1,3-Butylene glycol ex.) 5 9. Preservative appropriate amount 10. Residue of purified water 100 4) Shampoo production example A shampoo was produced according to the following formulation. Weight% 1. Lauryl sulfate triethanolamine 5 2. Polyoxyethylene lauryl ether sulfate Na 12 3.1,3-butylene glycol 4 4. Lauric acid diethanolamide 2 5. Disodium edetate 0.1 6. Hyougi extract (20% 1,3-Butylene glycol ex.) 10 7. Preservative proper amount 8. Residue of purified water as 100 5) Hair Liquid Production Example A hair liquid was produced according to the following formulation. Weight% 1. Ethanol 29 2. Polyoxypropylene butyl ether phosphoric acid 10 3. Polyoxypropylene monobutyl ether 5 4. Triethanolamine 1 5. White cedar extract (Ethanol, 1,3-BG, water (1: 1: 3) ex.) 5 6. Preservative proper amount 7. Residue of purified water 100 6) Example of production of body soap A body soap was produced according to the following formulation. Weight% 1. Potassium laurate 15 2. Potassium myristate 5 3. Propylene glycol 5 4. Hyougi extract (20% Propylene Glycol ex.) 15 5. pH adjuster Appropriate amount 6. Preservative proper amount 7. Residue of purified water 100 7) Preparation example of bath agent (A type) A bath agent was produced according to the following formulation. Weight% 1. Sodium hydrogen carbonate 58 2. Anhydrous sodium sulfate 30 3. Borax 2 4. Dry powder of Hyougi extract (40% Ethanol ex.) 10 8) Preparation example of bath agent (B type) A bath agent was produced according to the following formulation. Weight% 1. Refined jojoba oil 5 2. Poroxyethylene sorbitan monolaurate 20 3. Glycerin monostearate 5 4. Liquid paraffin 2 5. Lauric acid diethanolamide 3 6. Hyougi extract (50% Propylene glycol ex.) 25 7. Residue of purified water 100
【0013】[0013]
【実施例】各種外用製剤の使用試験 実施例で製造したローションおよび浴用剤を男女パネラ
ー(各15名)に1カ月間自由に使用してもらい使用感に
ついてのアンケート調査を求めた。その結果は、表1の
通りである。[Examples] Usage test of various external preparations Male and female panelists (15 persons each) were allowed to freely use the lotions and bath agents produced in the examples for one month, and a questionnaire survey on feeling of use was requested. The results are shown in Table 1.
【表1】 [Table 1]
【0014】[0014]
【発明の効果】本発明によるヒオウギ由来の細胞賦活剤
は、その効果に優れしかも安全性が高い。これを例え
ば、日常的に用いる各種の皮膚外用製剤に配合し、それ
らを繰り返し用いることによって、皮膚細胞を賦活化し
肌質を改善する効果や創傷治癒効果といった美容的効果
が得られる。すなわち、肌に潤い,つや,柔軟性,はり
などを保持させ、皮膚本来の恒常性を維持することがで
きる。本発明によるヒオウギのこのような新規な美容的
効果と、それに基づく応用法は、極めて日常的な方法に
よって人の美容と健康に役立つことにつながり、また植
物の有効利用の拡大ということからも産業上にもたらす
効果は大きい。EFFECTS OF THE INVENTION The cell stimulant derived from Hyougi according to the present invention is excellent in its effect and highly safe. By blending this with various skin external preparations that are routinely used and using them repeatedly, cosmetic effects such as an effect of activating skin cells to improve skin quality and a wound healing effect can be obtained. That is, it is possible to maintain the original homeostasis of the skin by keeping the skin moisturized, glossy, flexible, and supple. The novel cosmetic effect of Hyogi according to the present invention and the application method based on the novel cosmetic effect are useful for human beauty and health by extremely daily methods, and also from the viewpoint of expanding effective use of plants. The effect on top is great.
図1は、ヒオウギの20%Ethanol抽出物によるモルモッ
ト肝細胞の酸素消費量に与える影響を表したグラフであ
る。FIG. 1 is a graph showing the effect of 20% Ethanol extract of Hyougi on oxygen consumption in guinea pig hepatocytes.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 7/075 7/48 7/50 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location A61K 7/075 7/48 7/50
Claims (3)
物から、水、低級アルコール、ポリオール系有機溶媒か
ら選ばれる1種もしくは2種以上を用いて得られる抽出
物を含有する細胞賦活剤1. A cell activating agent containing an extract obtained by using one or more selected from water, a lower alcohol and a polyol organic solvent from a dried product of Hydrangea vulgaris or its rhizome.
物から得られる請求項第1項記載の細胞賦活剤を配合し
た皮膚外用組成物2. A composition for external application to the skin, which is obtained from a dried product of Hydrangea vulgaris or a rhizome of the family Iridaceae.
物から得られる請求項第1項記載の細胞賦活剤を配合し
た浴用組成物3. A bath composition containing the cell activator according to claim 1, which is obtained from a dried product of the iris family Hyougi or rhizome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30985893A JP3294694B2 (en) | 1993-11-15 | 1993-11-15 | Cell activator containing oat extract and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30985893A JP3294694B2 (en) | 1993-11-15 | 1993-11-15 | Cell activator containing oat extract and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07138179A true JPH07138179A (en) | 1995-05-30 |
| JP3294694B2 JP3294694B2 (en) | 2002-06-24 |
Family
ID=17998147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30985893A Expired - Fee Related JP3294694B2 (en) | 1993-11-15 | 1993-11-15 | Cell activator containing oat extract and its application |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3294694B2 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124499A (en) * | 1995-09-07 | 1997-05-13 | L'oreal Sa | Iridaceae plant extract and composition containing the same |
| EP0797985A1 (en) * | 1996-03-27 | 1997-10-01 | L'oreal | Use of an extract of iridaceas in the treatment of skin wrinkles |
| JPH09301884A (en) * | 1996-05-15 | 1997-11-25 | Ichimaru Pharcos Co Ltd | Testosterone 5 alpha-reductase inhibitor containing blackberry lily extract and alpha-hydroxyl acid and its application |
| JPH09301883A (en) * | 1996-05-15 | 1997-11-25 | Ichimaru Pharcos Co Ltd | Cell activator containing blackberry lily extract and alpha-hydroxyl acid and its application |
| JP2002121143A (en) * | 2000-10-13 | 2002-04-23 | Nonogawa Shoji Kk | Skin care preparation |
| WO2003015724A1 (en) * | 2001-08-21 | 2003-02-27 | Shiseido Company, Ltd. | Substances capable of potentiating laminin 5 productivity in epidermal cells and utilization thereof |
| JP2003128563A (en) * | 2001-10-25 | 2003-05-08 | Ichimaru Pharcos Co Ltd | Cosmetic composition, drink or food |
| JP2003137767A (en) * | 2001-08-21 | 2003-05-14 | Shiseido Co Ltd | Laminin 5 production promoter in epidermal cell |
| KR100638055B1 (en) * | 2000-03-20 | 2006-10-24 | 주식회사 코리아나화장품 | Cosmetic composition containing liver extract |
| CN100381435C (en) * | 2005-03-24 | 2008-04-16 | 深圳海王药业有限公司 | Shegan total flavonoid extract and its preparation method and its application in medicine preparation |
| US7413754B2 (en) | 2001-09-19 | 2008-08-19 | Bionorica Ag | Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones |
| JP2012131758A (en) * | 2010-12-24 | 2012-07-12 | Ajinomoto Co Inc | Cosmetic composition |
| EP2633848A1 (en) * | 2012-02-22 | 2013-09-04 | "Pulanna" sp. z o.o. | Natural multiphase cosmetics |
| JP2016199550A (en) * | 2016-05-17 | 2016-12-01 | ピアス株式会社 | EXPRESSION ACTIVATOR OF Bmal1 GENE AND EXPRESSION ACTIVATION METHOD OF Bmal1 GENE |
-
1993
- 1993-11-15 JP JP30985893A patent/JP3294694B2/en not_active Expired - Fee Related
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124499A (en) * | 1995-09-07 | 1997-05-13 | L'oreal Sa | Iridaceae plant extract and composition containing the same |
| US6471997B1 (en) * | 1995-09-07 | 2002-10-29 | Societe L'oreal S.A. | Iridaceae extract and compositions containing it |
| US6224850B1 (en) | 1996-03-27 | 2001-05-01 | Societe L'oreal S.A. | Antiwrinkle cosmetic/pharmaceutical compositions comprising iridaceae extracts |
| EP0797985A1 (en) * | 1996-03-27 | 1997-10-01 | L'oreal | Use of an extract of iridaceas in the treatment of skin wrinkles |
| WO1997035556A1 (en) * | 1996-03-27 | 1997-10-02 | L'oreal | Use of an extract of at least one iridaceous plant for treating wrinkles |
| FR2746641A1 (en) * | 1996-03-27 | 1997-10-03 | Oreal | USE OF AN EXTRACT OF AT LEAST ONE IRIDACEA IN THE TREATMENT OF WRINKLES |
| JPH09301884A (en) * | 1996-05-15 | 1997-11-25 | Ichimaru Pharcos Co Ltd | Testosterone 5 alpha-reductase inhibitor containing blackberry lily extract and alpha-hydroxyl acid and its application |
| JPH09301883A (en) * | 1996-05-15 | 1997-11-25 | Ichimaru Pharcos Co Ltd | Cell activator containing blackberry lily extract and alpha-hydroxyl acid and its application |
| KR100638055B1 (en) * | 2000-03-20 | 2006-10-24 | 주식회사 코리아나화장품 | Cosmetic composition containing liver extract |
| JP2002121143A (en) * | 2000-10-13 | 2002-04-23 | Nonogawa Shoji Kk | Skin care preparation |
| WO2003015724A1 (en) * | 2001-08-21 | 2003-02-27 | Shiseido Company, Ltd. | Substances capable of potentiating laminin 5 productivity in epidermal cells and utilization thereof |
| JP2003137767A (en) * | 2001-08-21 | 2003-05-14 | Shiseido Co Ltd | Laminin 5 production promoter in epidermal cell |
| US7413754B2 (en) | 2001-09-19 | 2008-08-19 | Bionorica Ag | Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones |
| JP2003128563A (en) * | 2001-10-25 | 2003-05-08 | Ichimaru Pharcos Co Ltd | Cosmetic composition, drink or food |
| CN100381435C (en) * | 2005-03-24 | 2008-04-16 | 深圳海王药业有限公司 | Shegan total flavonoid extract and its preparation method and its application in medicine preparation |
| JP2012131758A (en) * | 2010-12-24 | 2012-07-12 | Ajinomoto Co Inc | Cosmetic composition |
| EP2633848A1 (en) * | 2012-02-22 | 2013-09-04 | "Pulanna" sp. z o.o. | Natural multiphase cosmetics |
| JP2016199550A (en) * | 2016-05-17 | 2016-12-01 | ピアス株式会社 | EXPRESSION ACTIVATOR OF Bmal1 GENE AND EXPRESSION ACTIVATION METHOD OF Bmal1 GENE |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3294694B2 (en) | 2002-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3294694B2 (en) | Cell activator containing oat extract and its application | |
| US7655255B2 (en) | Topical composition for transdermal administration | |
| US5525331A (en) | Inhibitors of esterase-producing micro-organisms, for use primarily in deodorant compositions | |
| JP3223404B2 (en) | Hair restorer | |
| JPH07277939A (en) | Skin external preparation | |
| JPH0892057A (en) | Cosmetics containing coffee tree seed extract | |
| JP4117773B2 (en) | Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent | |
| US7262224B2 (en) | Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof | |
| JP3501832B2 (en) | Testosterone 5α-reductase inhibitor containing rhubarb extract and its application | |
| CN108542851A (en) | A kind of Chinese medicine moisturizing anti-chapping hand cream and preparation method thereof | |
| JPH09221410A (en) | Aging preventing skin ointment | |
| JP3881411B2 (en) | Composition suitable for external use | |
| CN104922008A (en) | Essence capable of removing color spots | |
| JPH0519527B2 (en) | ||
| KR102481125B1 (en) | A composition for skin anti-pollution containing a daughter-in-law navel extract | |
| JPH1029924A (en) | Antiaging agent | |
| US20060222689A1 (en) | Skin care compositions and methods | |
| KR20000053859A (en) | The hair-growing agent composition which is contained the extract from natural phellinus linteus and preparation method using the same | |
| CN113693966A (en) | Innovative whitening brightening freckle-removing cream and preparation method thereof | |
| KR20210090870A (en) | Cosmetic composition with excellent skin barrier using skin microbiome | |
| Hazen | Diseases of the Skin | |
| CN117883339A (en) | A composition containing Althaea officinalis root extract | |
| JPH1095704A (en) | Composition suitable for external use | |
| JPH09301883A (en) | Cell activator containing blackberry lily extract and alpha-hydroxyl acid and its application | |
| CN111529460A (en) | Mask composition, mask and preparation method of mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313532 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313532 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100405 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130405 Year of fee payment: 11 |
|
| LAPS | Cancellation because of no payment of annual fees |